Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ENLV
- Price
- 1.09
- Stock movement down
- -0.07 (-6.36%)
- Company name
- Enlivex Therapeutics Ltd
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 24.57M
- Ent value
- 25.01M
- Price/Sales
- -
- Price/Book
- 0.92
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -30.53%
- 1 year return
- -18.25%
- 3 year return
- -41.52%
- 5 year return
- -27.99%
- 10 year return
- -41.67%
Last updated: 2025-09-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ENLV does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 0.92 |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 23.86M |
| EPS (TTM) | -0.89 |
| FCF per share (TTM) | -0.66 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -548.00K |
| Operating income (TTM) | -16.15M |
| Net income (TTM) | -18.93M |
| EPS (TTM) | -0.89 |
| EPS (1y forward) | -0.59 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 2.77M |
| Net receivables | 1.40M |
| Total current assets | 27.11M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 4.94M |
| Total assets | 29.80M |
| Accounts payable | 92.00K |
| Short/Current long term debt | 765.00K |
| Total current liabilities | 2.79M |
| Total liabilities | 3.21M |
| Shareholder's equity | 26.59M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -13.95M |
| Capital expenditures (TTM) | 73.94K |
| Free cash flow (TTM) | -14.02M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -71.21% |
| Return on Assets | -63.54% |
| Return on Invested Capital | -70.30% |
| Cash Return on Invested Capital | -52.07% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.10 |
| Daily high | 1.12 |
| Daily low | 1.01 |
| Daily Volume | 945K |
| All-time high | 391.60 |
| 1y analyst estimate | 10.00 |
| Beta | 0.80 |
| EPS (TTM) | -0.89 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 1 Dec 2025 |
Downside potential
Loading...
Downside potential data
| ENLV | S&P500 | |
| Current price drop from All-time high | -99.74% | -1.46% |
| Highest price drop | -99.78% | -56.47% |
| Date of highest drop | 17 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -87.78% | -10.99% |
| Avg time to new high | 253 days | 12 days |
| Max time to new high | 2763 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
24.57M
Marketcap category
Small-cap
Description
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which is in phase I/II clinical trial for the treatment of Basal thumb osteoarthritis; and ENX-CL-06-001 to treat Psoriatic arthritis and is in phase I/II clinical trial. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Ness Ziona, Israel.
Employees
0
Website
Investor relations
-
SEC filings
CEO
Oren Hershkovitz
Country
USA
City
Nes-Ziona
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page